论文部分内容阅读
我科根据卫生部药政管理局关于新药临床研究(87)XL10号批件(倍半氧化羧乙基锗注射液及口服液)及卫生部药审办字第87号文件精神,受卫生部药政管理局委托,对广州军区后勤部药品检验所研制的倍半氧化羧乙基锗(代号Ge—132)注射液及口服液作Ⅰ期临床试验,报告如下:
In accordance with the spirit of the document No. 87 of the Ministry of Health Administration of Pharmaceutical Affairs of the Ministry of Health on Clinical Investigation of New Drugs (87) XL10 (Carbosulferoxyhalodeoxy Sulfoxylate Injection and Oral Solution) and Ministry of Health, the Ministry of Health The administrative bureau commissioned a phase I clinical trial of the injection of carbose sesquioxide (coded Ge-132) and oral liquid developed by the Drug Inspection Institute of the Guangzhou Military Region Logistics Department. The report is as follows: